Integrated Filing — IndAS



General information about company

Scrip Code 530549
NSE Symbol SHILPAMED
MSEI Symbol NOTLISTED
ISIN INE790G01031
Name of company SHILPA MEDICARE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 22-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment PHARMACETICAL
Start date and time of board meeting 22-05-2026   12:20:00
End date and time of board meeting 22-05-2026   14:40:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 10-02-2025
Indicate Company website link for updated RPT policy of the Company https://vbshilpa.com/policies-and-codes.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Appicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 20,111.00 59,703.00
Other income 689.00 3,814.00
Total income 20,800.00 63,517.00
2 Expenses
(a) Cost of materials consumed 6,738.00 20,599.00
(b) Purchases of stock-in-trade 650.00 2,211.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 425.00 (364.00)
(d) Employee benefit expense 3,001.00 11,099.00
(e) Finance costs 262.00 1,004.00
(f) Depreciation, depletion and amortisation expense 1,441.00 5,511.00
(f) Other Expenses
1 22-May-26 3,318.00 10,586.00
Total other expenses 3,318.00 10,586.00
Total expenses 15,835.00 50,646.00
3 Total profit before exceptional items and tax 4,965.00 12,871.00
4 Exceptional items 2,837.00 1,942.00
5 Total profit before tax 7,802.00 14,813.00
6 Tax expense
7 Current tax 567.00 1,099.00
8 Deferred tax 138.00 417.00
9 Total tax expenses 705.00 1,516.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 7,097.00 13,297.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 7,097.00 13,297.00
17 Other comprehensive income net of taxes (1.00) (11.00)
18 Total Comprehensive Income for the period 7,096.00 13,286.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,956.00 1,956.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 2,69,382.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.63 6.8
Diluted earnings (loss) per share from continuing operations 3.63 6.8
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.63 6.8
Diluted earnings (loss) per share from continuing and discontinued operations 3.63 6.8
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 46,287.00
Capital work-in-progress 3,680.00
Investment property 0.00
Goodwill 385.00
Other intangible assets 15,208.00
Intangible assets under development 26,015.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 1,22,277.00
Trade receivables, non-current 0.00
Loans, non-current 33,160.00
Other non-current financial assets
1 Other non-current financial assets 307.00
Total of other non-current financial assets 307.00
Total non-current financial assets 1,55,744.00
Deferred tax assets (net)
Other non-current assets
1 Other non-current assets 917.00
2 Right of use asset 1,993.00
Total of other non-current assets 2,910.00
Total non-current assets 2,50,229.00
2 Current assets
Inventories 17,503.00
Current financial asset
Current investments 0.00
Trade receivables, current 22,266.00
Cash and cash equivalents 915.00
Bank balance other than cash and cash equivalents 173.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 6,106.00
Total current financial assets 29,460.00
Current tax assets (net) 764.00
Other current assets
1 Other current assets 4,899.00
Total of other current assets 4,899.00
Total current assets 52,626.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 3,02,855.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,956.00
Other equity 2,69,382.00
Total equity attributable to owners of parent 2,71,338.00
Non controlling interest
Total equity 2,71,338.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,429.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 211.00
Total of other non-current financial liabilities 211.00
Total non-current financial liabilities 1,640.00
Provisions, non-current 526.00
Deferred tax liabilities (net) 1,577.00
Deferred government grants, Non-current
Other non-current liabilities
1 Lease Liability 132.00
Total of other non-current liabilities 132.00
Total non-current liabilities 3,875.00
Current liabilities
Current financial liabilities
Borrowings, current 11,571.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 504.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 8,001.00
Total Trade payable 8,505.00
Other current financial liabilities
1 Other financial liabilities 4,412.00
Total of other current financial liabilities 4,412.00
Total current financial liabilities 24,488.00
Other current liabilities 1,784.00
1 Other current liabilities 1,727.00
2 Lease Liability 57.00
Total of other current liabilities 1,784.00
Provisions, current 1,370.00
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 27,642.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 31,517.00
Total equity and liabilites 3,02,855.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 1.00 16.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 (5.00)
5 Total Other comprehensive income (1.00) (11.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 14,813.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,004.00
Adjustments for decrease (increase) in inventories (3,462.00)
Adjustments for decrease (increase) in trade receivables, current (3,486.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets (20.00)
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 4,321.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities (2,859.00)
Adjustments for depreciation and amortisation expense 5,511.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (2,650.00)
Adjustments for dividend income 25.00
Adjustments for interest income 2,446.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (2,641.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (6,753.00)
Net cash flows from (used in) operations 8,060.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,060.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 6,000.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 2,778.00
Other cash receipts from sales of interests in joint ventures 4,964.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 12,744.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 1,202.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 2,641.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (6,715.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 3,348.00
Repayments of borrowings 0.00
Payments of lease liabilities 58.00
Dividends paid 978.00
Interest paid 936.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 1,376.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 661.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (50.00)
Net increase (decrease) in cash and cash equivalents 611.00
Cash and cash equivalents cash flow statement at beginning of period 476.00
Cash and cash equivalents cash flow statement at end of period 1,087.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BNPS AND ASSOCIATES LLP Yes 31-05-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Shilpa Medicare Limited Vishnukant.C. Bhutada Managing Director Remuneration Approved 175.00 (15.79) (13.66)
2 Shilpa Medicare Limited Omprakash Inani Non-executive Chairman Any other transaction Sitting Fees Approved 2.50 (0.90) (1.35)
3 Shilpa Medicare Limited Deepak Innani Relative to Director Remuneration Approved 58.68 (6.44) (6.44)
4 Shilpa Medicare Limited Ramakant Innani Relative to Director Remuneration Approved 61.70 (6.82) (6.82)
5 Shilpa Medicare Limited Ravi Kumar Innani Relative to Director Remuneration Approved 45.65 (4.59) (4.59)
6 Shilpa Medicare Limited Sagar Innani Relative to Director Remuneration Approved 8.01 (1.00) (1.00)
7 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Purchase of goods or services Approved 0.00 0.00 0.00
8 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Any other transaction Interest Income (Loan) Approved 187.94 0.00 0.00
9 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Any other transaction Loan Receivable Approved 0.00 5,319.99 5,564.21
10 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Any other transaction Receivable Approved 0.00 3.33 0.00
11 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Any other transaction Trade payable (incl prov for exp) Approved 0.00 (1,236.34) (1,285.74)
12 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 202.82 139.78
13 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Any other transaction Investment in equity Shares Approved 0.00 77.63 77.63
14 Shilpa Medicare Limited Koanna Healthcare Ltd, United Kingdom Wholly owned Subsidiary Any other transaction Interest Income (Loan) Approved 38.21 0.00 0.00
15 Shilpa Medicare Limited Koanna Healthcare Ltd, United Kingdom Wholly owned Subsidiary Purchase of goods or services Approved 45.74 0.00 0.00
16 Shilpa Medicare Limited Koanna Healthcare Ltd, United Kingdom Wholly owned Subsidiary Any other transaction Loan given during the year Approved 172.76 0.00 0.00
17 Shilpa Medicare Limited Koanna Healthcare Ltd, United Kingdom Wholly owned Subsidiary Any other transaction Loan Receivable Approved 0.00 1,028.51 1,258.52
18 Shilpa Medicare Limited Koanna Healthcare Ltd, United Kingdom Wholly owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 206.41 258.28
19 Shilpa Medicare Limited Koanna Healthcare Ltd, United Kingdom Wholly owned Subsidiary Any other transaction Investment in equity Shares Approved 0.00 0.10 0.10
20 Shilpa Medicare Limited Koanna Healthcare Ltd, United Kingdom Wholly owned Subsidiary Any other transaction Trade payable (inc Prov for exp) Approved 0.00 (609.60) 0.00
21 Shilpa Medicare Limited Reva Medicare Pvt. Ltd. Joint Venture Any other transaction Commission charges Approved 19.52 0.00 0.00
22 Shilpa Medicare Limited Reva Medicare Pvt. Ltd. Joint Venture Any other transaction Other Income Approved 2.10 0.00 0.00
23 Shilpa Medicare Limited Reva Medicare Pvt. Ltd. Joint Venture Any other transaction Trade Payable Approved 0.00 (13.68) (8.78)
24 Shilpa Medicare Limited Reva Medicare Pvt. Ltd. Joint Venture Any other transaction Commission Accrued but not paid Approved 0.00 (28.69) (46.72)
25 Shilpa Medicare Limited Reva Medicare Pvt. Ltd. Joint Venture Any other transaction Receivable Approved 0.00 0.83 0.00
26 Shilpa Medicare Limited Reva Medicare Pvt. Ltd. Joint Venture Any other transaction Investment in equity shares Approved 0.00 0.50 0.50
27 Shilpa Medicare Limited Maia Pharmaceuticals INC. USA Associate Company Any other transaction Investment in Pref shares Approved 0.00 795.69 795.69
28 Shilpa Medicare Limited Shilpa Pharma INC. USA Wholly-owned Subsidiary Any other transaction Interest Income (Loan) Approved 72.78 0.00 0.00
29 Shilpa Medicare Limited Shilpa Pharma INC. USA Wholly-owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 161.14 249.49
30 Shilpa Medicare Limited Shilpa Pharma INC. USA Wholly-owned Subsidiary Any other transaction Loan Receivable Approved 0.00 1,922.35 2,049.27
31 Shilpa Medicare Limited Shilpa Pharma INC. USA Wholly-owned Subsidiary Any other transaction Investment in equity shares (application money converted into equity) Approved 1,745.00 0.07 1,745.07
32 Shilpa Medicare Limited Shilpa Pharma INC. USA Wholly-owned Subsidiary Any other transaction Paid towards Share Application money Approved 0.00 1,745.00 0.00
33 Shilpa Medicare Limited Sravathi Advance Process Technologies Pvt. Ltd. Associate Any other transaction Investment in equity shares Approved 0.00 3,995.98 2,089.99
34 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction sale of services Approved 0.00 0.00 0.00
35 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Sales of Capital Goods Approved 3.36 0.00 0.00
36 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Other income Approved 0.00 0.00 0.00
37 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Sales -Wind Energy Approved 100.08 0.00 0.00
38 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Interest Income (Loan) Approved 439.14 0.00 0.00
39 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Loan given during the year(incl Interest accrued till last year) Approved 5,807.00 0.00 0.00
40 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Loan Receivable Approved 0.00 9,463.42 15,270.42
41 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 230.13 0.43
42 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Receivable Approved 0.00 44.57 0.00
43 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Corp Guarantee to Banks **(new) Approved 0.00 14,042.00 14,042.00
44 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Corporate Guarantee Income Approved 70.79 0.00 0.00
45 Shilpa Medicare Limited Shilpa Biocare Pvt. Ltd Wholly-owned Subsidiary Any other transaction Investment in equity shares Approved 0.00 36,965.00 36,965.00
46 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Sales of Capital Goods Approved 106.67 0.00 0.00
47 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Purchase of goods or services Approved 4.77 0.00 0.00
48 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Interest Income (Loan) Approved 2.67 0.00 0.00
49 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Receivable Approved 0.00 76.57 0.47
50 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Trade Payable Approved 0.00 (42.66) (4.66)
51 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Loan given during the year(incl Interest accrued till last year) Approved 435.00 0.00 0.00
52 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Loan given received back Approved 440.00 0.00 0.00
53 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Loan Receivable Approved 0.00 5.00 0.00
54 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 106.58 11.93
55 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Investment in equity shares Approved 0.00 71,700.95 71,700.95
56 Shilpa Medicare Limited Shilpa Biologicals Pvt. Ltd. Wholly-owned Subsidiary Any other transaction Advance received Approved 5.38 0.00 (5.38)
57 Shilpa Medicare Limited Shilpa Foundation Trust in which key management are the board of trustees or Director are Trustee Any other transaction Corporate Social Responsibility Expenses Approved 58.90 0.00 0.00
58 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Sale of goods or services Approved 52.12 0.00 0.00
59 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Purchase of goods or services Approved 285.86 0.00 0.00
60 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Any other transaction Purchases of Capital Goods Approved 252.96 0.00 0.00
61 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Any other transaction Receivable Approved 0.00 0.00 0.49
62 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Any other transaction Investment in Equity shares Approved 0.00 6,577.97 6,577.97
63 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Any other transaction Investment in Pref shares Approved 0.00 390.00 390.00
64 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Any other transaction Dividend on Pref Shares Approved 12.43 0.00 0.00
65 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Any other transaction Dividend accrued but not received (Preference shares) Approved 0.00 56.17 68.61
66 Shilpa Medicare Limited FTF Pharma Pvt Ltd Wholly-owned Subsidiary Any other transaction Trade Payable Approved 0.00 (63.94) (252.60)
67 Shilpa Medicare Limited Koanna Healthcare Canada INC Wholly-owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 16.99 0.00
68 Shilpa Medicare Limited Koanna Healthcare Canada INC Wholly-owned Subsidiary Any other transaction Investment in equity shares(disposed during the year) Approved 44.49 1,682.69 0.00
69 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Sales -(cross charges) Approved 673.74 0.00 0.00
70 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Sale of goods or services Approved 411.62 0.00 0.00
71 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Sales -Wind Energy Approved 4.66 0.00 0.00
72 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Sales of Capital Goods Approved 69.19 0.00 0.00
73 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Electrical Charges -reimbursement received Approved 8.81 0.00 0.00
74 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Purchase of goods or services Approved 12,299.42 0.00 0.00
75 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction R&D Expense (Product Analysis charges ) Approved 202.50 0.00 0.00
76 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Purchase of Capital Goods Approved 60.71 0.00 0.00
77 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Interest Income (Loan) Approved 285.87 0.00 0.00
78 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 489.71 698.03
79 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Trade Payable(including transit Pur) Approved 0.00 4,910.69 4,529.82
80 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Loan given during the year Approved 2,280.00 0.00 0.00
81 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Loan given received back Approved 4,580.00 0.00 0.00
82 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Loan Receivable Approved 0.00 9,549.01 7,249.01
83 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Receivable Approved 0.00 454.53 677.11
84 Shilpa Medicare Limited Shilpa Pharma Lifesciences Limited Wholly owned Subsidiary Any other transaction Investment in Equity shares Approved 0.00 1,000.00 1,000.00
85 Shilpa Medicare Limited Indo Biotech SDN. BHD Wholly owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 281.16 314.97
86 Shilpa Medicare Limited Indo Biotech SDN. BHD Wholly owned Subsidiary Any other transaction Loan Receivable Approved 0.00 143.90 153.40
87 Shilpa Medicare Limited Indo Biotech SDN. BHD Wholly owned Subsidiary Any other transaction Investment in equity shares Approved 0.00 4.42 4.42
88 Shilpa Medicare Limited Koanna International FZ LLC. UAE Wholly owned Subsidiary Any other transaction Interest Income (Loan) Approved 23.96 0.00 0.00
89 Shilpa Medicare Limited Koanna International FZ LLC. UAE Wholly owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 167.20 210.02
90 Shilpa Medicare Limited Koanna International FZ LLC. UAE Wholly owned Subsidiary Any other transaction Loan Receivable Approved 0.00 648.18 690.98
91 Shilpa Medicare Limited Koanna International FZ LLC. UAE Wholly owned Subsidiary Any other transaction Investment in Equity shares Approved 0.00 1.98 1.98
92 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Interest Income (Loan) Approved 35.65 0.00 0.00
93 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 137.50 108.51
94 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Service fee paid Approved 378.06 0.00 0.00
95 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Commission Charges Approved 8.94 0.00 0.00
96 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Loan repaid during the year Approved 358.09 0.00 0.00
97 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Loan Receivable Approved 0.00 1,318.41 997.41
98 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Investment in Equity shares Approved 0.00 6.24 6.24
99 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Receivable Approved 0.00 299.12 0.00
100 Shilpa Medicare Limited Koannaa Healthcare Spain, S.L. Spain Wholly owned Subsidiary Any other transaction Trade Payable Approved 0.00 (695.16) (375.50)
101 Shilpa Medicare Limited Sampra Corporate Holdings Pvt Ltd Wholly owned Subsidiary Any other transaction Investment in Equity shares Approved 0.00 951.00 951.00
102 Shilpa Medicare Limited Sampra Corporate Holdings Pvt Ltd Wholly owned Subsidiary Any other transaction Loan repaid Approved 24.00 0.00 0.00
103 Shilpa Medicare Limited Sampra Corporate Holdings Pvt Ltd Wholly owned Subsidiary Any other transaction Loan Payable Approved 0.00 (1,453.07) (1,429.07)
104 Shilpa Medicare Limited Sampra Corporate Holdings Pvt Ltd Wholly owned Subsidiary Any other transaction Interest Paid (Loan) Approved 53.92 0.00 0.00
105 Shilpa Medicare Limited Sampra Corporate Holdings Pvt Ltd Wholly owned Subsidiary Any other transaction Interest due but not paid (Loan) Approved 0.00 (54.71) (97.77)
106 Shilpa Medicare Limited Shilpa Lifesciences Private Limited Step down Subsidiary Any other transaction Interest Income (Loan) Approved 11.51 0.00 0.00
107 Shilpa Medicare Limited Shilpa Lifesciences Private Limited Step down Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 11.58 0.00
108 Shilpa Medicare Limited Shilpa Lifesciences Private Limited Step down Subsidiary Any other transaction Loan Receivable Approved 0.00 307.83 307.83
109 Shilpa Medicare Limited Makindus LLC USA Wholly owned Subsidiary Any other transaction Investment in Equity shares Approved 0.00 454.20 454.20
110 Shilpa Medicare Limited Pilnova Pharma INC USA Wholly owned Subsidiary Any other transaction Investment in Equity shares Approved 0.00 0.08 0.08
111 Shilpa Medicare Limited Pilnova Pharma INC USA Wholly owned Subsidiary Any other transaction Loan given during the year Approved 319.72 0.00 0.00
112 Shilpa Medicare Limited Pilnova Pharma INC USA Wholly owned Subsidiary Any other transaction Loan receivable Approved 0.00 1,709.25 2,153.39
113 Shilpa Medicare Limited Pilnova Pharma INC USA Wholly owned Subsidiary Any other transaction Interest Income (Loan) Approved 69.07 0.00 0.00
114 Shilpa Medicare Limited Pilnova Pharma INC USA Wholly owned Subsidiary Any other transaction Interest accrued but not received (Loan) Approved 0.00 117.32 198.80
115 Shilpa Medicare Limited Pilnova Pharma INC USA Wholly owned Subsidiary Any other transaction Receivable Approved 0.00 410.36 437.45
116 Shilpa Medicare Limited Koanna Healthcare GMBH, Austria Wholly owned Subsidiary Any other transaction Purchase of Capital Goods Approved 29.14 0.00 0.00
Total value of transaction during the reporting period 32,945.79